HOME
FAQs
BLOG
SUBMIT LISTING/OFFER
EXPERTS DIRECTORY
✕
Filter by
Categories
Tags
Authors
Show all
All
Patents
All
505(b)(2)
Advertising
AI
alternative path
application
artificial intelligence
Asset Protection
automation
Backup Plan
board of directors
Business strategy
Buyers
cdc
CDC impact
CEO
Chemistry
Clinical Trials
CMS
Combinations
competition
creativity
deadlines
debt
Divesting
documents
Due Diligence
escrow
extending a patent
FDA
FDA Approval
financial impact
Grants
GRAS
history
Hold
How-to
Income
ingenuity
Innovation
institutional path
invention
Investing
investment strategy
IP Ownership
IP Strategy
IRS
Juggling
License
loan
market value
Marketing
Medicaid
Medical devices
medical patent
Medical Patents
Medicare
multiple patents
orphan drugs
Patent
Patent Licensing
Patent Maestro
Patent Strategy
patents
Patients
phase III
Phase IV
planning
Pre-Patent testing
problems
Process
profit
Remaining Patent Term
risk management
ROI
Sell
Sellers
stock split
stocks
Strategy
Supply Chain
tax
time
Timing
Transfers
value
All
admin
Kenneth Pearce
August 3, 2026
Waylaid in Phase III: What to Do When the FDA Panel Questions Your Foundation
June 29, 2026
Drive Your Medical Invention Down the FDA Autobahn in the Passing Lane
February 16, 2026
The 505(b)(2) Advantage: “Hybrid” is the Power Move in 2026